Genentech, Inc. - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 136 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Genentech, Inc. - Product Pipeline Review - 2014" provides data on the Genentech, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Genentech, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Genentech, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Genentech, Inc. - Brief Genentech, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Genentech, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Genentech, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Genentech, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Genentech, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Genentech, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Genentech, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Genentech, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Genentech, Inc. and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Genentech, Inc. Snapshot 6
Genentech, Inc. Overview 6
Key Information 6
Key Facts 6
Genentech, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Genentech, Inc. - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Pipeline Products - Out-Licensed Products 19
Genentech, Inc. - Pipeline Products Glance 21
Genentech, Inc. - Late Stage Pipeline Products 21
Genentech, Inc. - Clinical Stage Pipeline Products 22
Genentech, Inc. - Early Stage Pipeline Products 26
Genentech, Inc. - Drug Profiles 29
RG-7446 29
apitolisib 31
crenezumab 33
etrolizumab 35
ipatasertib 37
lampalizumab 39
MHAA-4549A 40
pictilisib 41
quilizumab 43
RG-7446 + bevacizumab 45
RG-7593 46
RG-7596 48
RG-7597 50
RG-7599 52
RG-7652 54
RG-7667 55
rontalizumab 56
GDC-0032 57
TNX-234 58
cobimetinib 59
DMUC-5754-A 61
GDC-0084 62
GDC-0425 63
GDC-0834 64
GDC-0853 65
GDC-0994 66
parsatuzumab 67
RG-7446 + vemurafenib 69
RG-7450 70
RG-7598 71
RG-7600 73
RG-7624 74
RG-7636 75
RG-7741 76
BV-6 77
Compound-29 79
CS-3 80
G-007-LK 81
G-244-LM 82
GNE-293 83
GNE-317 84
GNE-7915 85
Monoclonal Antibody 30D8 86
Monoclonal Antibody To Inhibit Tau For Alzheimers Disease 87
MV-1 88
Nampt Inhibitors 89
Small Molecules To Inhibit JAK2 For Cancer 90
Small Molecules To Inhibit JAK2 For Myeloproliferative Neoplasms 91
Small Molecules To Inhibit Mammalian Rapamycin Kinase For Cancer 92
Small Molecules To Inhibit NAMPT For Cancer 93
Triazolopyridine-9 94
AMRBAC-1 95
AMRBAC-2 96
AMRBAC-3 97
Benzoxazepin PI3K Inhibitors 98
Compound-37 99
Small Molecules For Bacterial Infections 100
Small Molecules To inhibit Human Lactate Dehydrogenase 101
Small Molecules To Inhibit Jak1/2 For Hematopoietic and Immunologic diseases 102
Small Molecules To inhibit PI3-Kinase Delta For Inflammatory and Leukocyte disorders 103
Small molecules To Inhibit Pim Kinase For Cancer 104
Genentech, Inc. - Pipeline Analysis 105
Genentech, Inc. - Pipeline Products by Therapeutic Class 105
Genentech, Inc. - Pipeline Products by Target 108
Genentech, Inc. - Pipeline Products by Route of Administration 111
Genentech, Inc. - Pipeline Products by Molecule Type 112
Genentech, Inc. - Pipeline Products by Mechanism of Action 113
Genentech, Inc. - Recent Pipeline Updates 116
Genentech, Inc. - Dormant Projects 125
Genentech, Inc. - Discontinued Pipeline Products 126
Discontinued Pipeline Product Profiles 126
Genentech, Inc. - Company Statement 128
Genentech, Inc. - Locations And Subsidiaries 129
Head Office 129
Other Locations & Subsidiaries 129
Genentech, Inc. - Key Manufacturing Facilities 130
Appendix 131
Methodology 131
Coverage 131
Secondary Research 131
Primary Research 131
Expert Panel Validation 131
Contact Us 132
Disclaimer 132

List of Tables
Genentech, Inc., Key Information 10
Genentech, Inc., Key Facts 10
Genentech, Inc. - Pipeline by Indication, 2014 13
Genentech, Inc. - Pipeline by Stage of Development, 2014 17
Genentech, Inc. - Monotherapy Products in Pipeline, 2014 18
Genentech, Inc. - Combination Treatment Modalities in Pipeline, 2014 19
Genentech, Inc. - Partnered Products in Pipeline, 2014 20
Genentech, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 21
Genentech, Inc. - Out-Licensed Products in Pipeline, 2014 23
Genentech, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 24
Genentech, Inc. - Phase III, 2014 25
Genentech, Inc. - Phase II, 2014 26
Genentech, Inc. - Phase I, 2014 28
Genentech, Inc. - Preclinical, 2014 30
Genentech, Inc. - Discovery, 2014 32
Genentech, Inc. - Pipeline by Therapeutic Class, 2014 110
Genentech, Inc. - Pipeline by Target, 2014 113
Genentech, Inc. - Pipeline by Route of Administration, 2014 115
Genentech, Inc. - Pipeline by Molecule Type, 2014 116
Genentech, Inc. - Pipeline Products by Mechanism of Action, 2014 118
Genentech, Inc. - Recent Pipeline Updates, 2014 120
Genentech, Inc. - Dormant Developmental Projects,2014 129
Genentech, Inc. - Discontinued Pipeline Products, 2014 130
Genentech, Inc., Other Locations 133
Genentech, Inc., Key Manufacturing Facilities 134